ORCIPRENALINE 2 MG — DIN 02236565
ORCIPRENALINE SULFATE : 2 MG · APOTEX INC · SYRUP · wholesale supply in Canada
Health Canada status: APPROVED
What is ORCIPRENALINE?
ORCIPRENALINE 2 MG contains ORCIPRENALINE SULFATE : 2 MG. It is listed in the Health Canada Drug Product Database under DIN 02236565, held by APOTEX INC, supplied as SYRUP for ORAL administration. Health Canada currently lists it as approved, status dated 17-Sep-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A). This DIN is not currently being marketed in Canada, so it is sourced to order where a compliant route exists rather than held in stock.
What is ORCIPRENALINE used for?
Bronchial asthma, chronic bronchitis, pulmonary emphysema. May be useful for bronchospasm in sarcoidosis, silicosis, carcinoma of the lung and tuberculosis. Not for acute bronchospasm.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Orciprenaline in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Orciprenaline, across 7 DINs, of which 0 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| BOEHRINGER INGELHEIM (CANADA) LTD LTEE | 2 | 0 | ALUPENT SYR 10MG/5.0ML, ALUPENT TAB 20MG | No marketed DIN |
| AA PHARMA INC | 1 | 0 | ORCIPRENALINE | No marketed DIN |
| APOTEX INC | 1 | 0 | ORCIPRENALINE | No marketed DIN |
| RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | 1 | 0 | RATIO-ORCIPRENALINE SYRUP 2MG/ML | No marketed DIN |
| TANTA PHARMACEUTICALS INC | 1 | 0 | TANTA ORCIPRENALINE SYRUP - SYR 2MG/ML | No marketed DIN |
| TECHNILAB PHARMA INC. | 1 | 0 | ORCIPREN | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 2 MG |
|---|---|
| Dosage form | SYRUP |
| Route | ORAL |
| Pack configuration (monograph) | Amber-coloured bottles containing 250 mL of clear syrup. |
| Storage | Store at room temperature (15 - 30°C). Protect from exposure to light. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Orciprenaline |
|---|---|
| ATC code | R03CB03 |
| AHFS class | 12:12.08.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02236565 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2236565 |
| Brand name | ORCIPRENALINE |
| Generic / active ingredient | ORCIPRENALINE SULFATE : 2 MG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | R03CB03 |
| ATC anatomical main group | R — Respiratory system |
| ATC therapeutic subgroup | R03CB |
| Current status | APPROVED |
| Status date | 17-Sep-2021 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Adults: 20 mg (10 mL) 3-4 times daily. Adolescents (12-18): 20 mg (10 mL) 3 times daily. Children (4-12): 10 mg (5 mL) 3 times daily. Max daily dose: 80 mg. Administer orally.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity to drug/ingredients; hypertrophic obstructive cardiomyopathy; cardiac arrhythmias with tachycardia; use with beta-blockers; tocolytic use in premature labour/threatened abortion.
Warnings and precautions
Not for acute/deteriorating asthma. Use with care in patients with hypertension, coronary artery disease, CHF, diabetes, glaucoma, or hyperthyroidism. Risk of serious hypokalemia and cardiac effects.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
0 of 7 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| ALUPENT SYR 10MG/5.0ML | 10 MG / 5 ML | SYRUP | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 00249920 |
| ALUPENT TAB 20MG | 20 MG | TABLET | BOEHRINGER INGELHEIM (CANADA) LTD LTEE | CANCELLED POST MARKET | 00003891 |
| ORCIPREN | 10 MG / 5 ML | SYRUP | TECHNILAB PHARMA INC. | CANCELLED POST MARKET | 02229862 |
| ORCIPRENALINE | 2 MG | SYRUP | AA PHARMA INC | DORMANT | 02236783 |
| RATIO-ORCIPRENALINE SYRUP 2MG/ML | 2 MG | SYRUP | RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED | CANCELLED POST MARKET | 02152568 |
| TANTA ORCIPRENALINE SYRUP - SYR 2MG/ML | 2 MG | SYRUP | TANTA PHARMACEUTICALS INC | CANCELLED POST MARKET | 02192675 |
2 · Same class — other molecules in ATC R03CB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Orciprenaline | ALUPENT SYR 10MG/5.0ML · ALUPENT TAB 20MG · ORCIPREN · ORCIPRENALINE · +2 more | 7 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC R03C
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| R03CC | Fenoterol · Salbutamol · Terbutaline | 23 | 1 |
| R03CA | Ephedrine | 14 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.